| Literature DB >> 31579983 |
Morteza Akbari1,2,3, Navid Shomali2,4,5, Afsaneh Faraji2, Dariush Shanehbandi2, Milad Asadi2, Ahad Mokhtarzadeh2, Aliakbar Shabani3, Behzad Baradaran2.
Abstract
Colorectal cancer (CRC) is one of the leading causes of death worldwide. Recently, the role of cancer stem cells (CSCs) has been highlighted as a crucial emerging factor in chemoresistance, cancer relapse, and metastasis. CD133 is a surface marker of CSCs and has been argued to have prognostic and therapeutic values in CRC along with its related pathways such as Wnt, Notch, and hedgehog. Several studies have successfully applied targeted therapies against CD133 in CRC models namely bispecific antibodies (BiAbs) and anti-Wnt and notch pathways agents. These studies have yielded initial promising results in this regard. However, none of the therapeutics have been used in the clinical setting and their efficacy and adverse effects profile are yet to be elucidated. This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.Entities:
Keywords: CD133; cancer stem cells; chemoresistance; colorectal cancer; targeted therapy
Year: 2019 PMID： 31579983 DOI： 10.1002/cbin.11243
Source DB: PubMed Journal: Cell Biol Int ISSN： 1065-6995 Impact factor: 3.612